Vascular Biogenics Ltd. announced that it has completed enrolment into a late-stage trial of its lead experimental drug, ofranergene obadenovec, in patients with a brain tumour. The Phase III study involves 256 patients with recurrent glioblastoma, which is an aggressive form of cancer in the brain. The company said that the enrolment has been completed five months ahead of schedule. The study is intended to generate data required to support the registration of the medicine, the company said. Ofranergene obadenovec has previously shown positive results in several tumour types, including survival benefit in glioblastoma. VBL hopes that the Phase III study will confirm the favourable findings. The company expects to announce an interim analysis of the trial in the middle of 2017 and top-line results at the start of 2018.